MedTrace Logo

Same-day Long-acting Reversible Contraception for Medication Abortion

NCT01356927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-04-07

No results posted yet for this study

Summary

Contraception after abortion is an important public health issue, as women who have an abortion are at high risk for additional unintended pregnancy. In the context of first trimester medical abortion, the standard of care is to administer long-acting reversible contraception, including the etonogestrel implant (Implanon) and depot medroxyprogesterone acetate (DMPA), at a follow-up appointment after the abortion.

The investigators plan to conduct a prospective observational pilot study to evaluate the satisfaction of subjects who have selected either the contraceptive implant or DMPA given on the first day of medical abortion, as opposed to at a follow-up appointment. The investigators will also assess the continuation of DMPA and Implanon at 3, 6, 9, and 12 months after the initial date of administration. In addition, the investigators will assess the total days of bleeding after the abortion, follow-up rate for evaluation of completion of medical abortion, and efficacy of medical abortion.

A total of 40 participants will be recruited, 20 who choose Implanon and 20 who choose DMPA. They will be asked to fill out questionnaires during the course of the study, and will be followed for one year. The study duration including data analysis will be two years.

Conditions

  • Abortion; Induced

Interventions

DRUG

DMPA

DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion

DRUG

Etonogestrel implant

Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion

Sponsors & Collaborators

  • Family Planning Fellowship

    collaborator OTHER

  • Boston University

    lead OTHER

Principal Investigators

  • Sarita Sonalkar, MD · Boston University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356927 on ClinicalTrials.gov